It's time for me to come to the ramparts even though it may mean a down day tomorrow - I post quite infrequently and it usually happens that the stock declines the next day - call it the smithlink syndrome, I guess. Anyway, here goes:

I am the originator of "It's the science, stupid!" and have refrained from posting on this board in favor of the other board. However, I feel my viewpoint is better heard here at this time.

Emblematic of the biotechnology industry is its very lengthy timeline. Patience, I know, can be very trying, but you must accept this as a given from the beginning. What we as current stockholders in Enzo are looking at is the very transformation of medical science into the 21st century. The promise of gene therapy is truly awesome and its fulfillment will bring spectacular benefits to the human condition and untold riches to the companies that succeed.

So I implore you to stay out of the counting house and exercise continuing patience. There is no better indicator of a management's concern in building shareholder value than its own stake and I remind you that the Rabbani's each own 1.8 million shares and Barry 1.1 million, including options. Building shareholder value does not mean sacrificing STRATEGIC decisions that must be made for the long term success of this company.

Enzo to this day remains little known in investement circles because the big brokerage houses' analysts have their collective heads in the sand. You would be surprised at the limited knowledge and understanding of and, finally, belief in Enzo's science even in the biotech industry. As Barry once told me, "They don't know what we're doing." Yet, in their last press release, Enzo has been quite upfront, but they're not being heard. The company does not have to shout. IF YOU BUILD IT, THEY WILL COME.

I'm sure an investment banking relationship will be on board when it is needed, for partnering, joint ventures or raising additional capital.

The FDA is not blind, but cautious, especially in light of the previous problems encountered with gene therapy reporting. They have always looked at viral load in approving immune therapies in the past. Enzo's work is so profound, I believe the regularory agency is on a learning curve and Enzo is the teacher. Graduation day is not years away. The paper to be presented in early June has weight and is important. And remember, all this is really past history. Enzo's scientists are further along than this. The intellectual property here is immense, in my opinion. It's not hundreds of millions of dollars in R & D, it's a small band of brilliant and dedicated researchers working with crackerjack p.i.'s that's going to bring all this home for us and humanity.

As a security analyst and portfolio manager, I feel any valuation under $80 a share, translating to a market capitalization of $2 billion, is a license to steal. Amgen, the daddy of the biotechs, TO DATE, has a market cap today in excess of $60 billion. But what is the future of biotech? - Yes, gene therapy. You shouldn't need a supercomputer to figure this one out.

In the end we'll kiss the ground they and Enzo's management walks on. PATIENCE, please. It's the science, stupid!
 --------------------------------------------------------------------------------